J&J Wins EMA Approval for Darzalex Home Use After Fifth Dose
Johnson & Johnson’s Darzalex received EMA approval for self-administration after the fifth dose across all ten indications, enabling patient or caregiver dosing at home following proper training. GlobalData forecasts Darzalex sales will peak at $7.6 billion in 2028, with home use helping shield subcutaneous formulations from biosimilar competition.
1. Label Expansion and Approval Details
The European Medicines Agency’s CHMP approved a Type II label change for Darzalex subcutaneous formulation, authorizing patient or caregiver self-administration after the fifth dose. The expansion covers all ten approved indications, from multiple myeloma to light chain amyloidosis and smouldering myeloma, contingent on training and provider assessment.
2. Home Administration Benefits
Enabling at-home dosing reduces dozens of clinic visits over a full treatment course, lowers logistical barriers, and may improve patient adherence. The shift also allows healthcare systems to reallocate infusion resources and offers greater convenience for transplant-eligible and ineligible myeloma patients.
3. Sales Forecast and Biosimilar Defense
Analyst forecasts project Darzalex sales peaking at $7.6 billion in 2028, driven by expanded home use. The subcutaneous at-home model provides near-term protection against biosimilar erosion as the intravenous patent nears expiration, though rising competition from monoclonal antibodies may pressure sales beyond 2028.